Two distinct subtypes discovered, each with dramatically different risks of recurrence Patients with more aggressive subtype can be monitored vigilantly for recurrence and possible treatment, while ...

A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...

A pancreatic neuroendocrine tumor (PNET) develops in the pancreas from a type of cell known as a neuroendocrine, or an endocrine, cell. These cells manufacture and release hormones such as insulin and ...

Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer. Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix ...

A team of department faculty and trainees recently published their research “Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance” in Pancreas.

Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center. Second-line gemcitabine ...

A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...

SAN FRANCISCO — Treatment with cabozantinib (Cometriq, Exelixis) has shown promising objective tumor responses and progression-free survival in patients with advanced carcinoid and pancreatic ...

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery].

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) arise from cells of the embryological gut. Most commonly, the primary lesion is located in the gastric mucosa, the small and large intestine, ...